Investor Presentaiton
Addressing the emerging oligonucleotides adjacent market
On track to benefit from synergistic market opportunities
Synergistic opportunities
Commercial readiness around YE 2021
Significant interest expressed by leading customers; established
customer relationships within overlapping customer bases
Initialization
✓ Commercial modified oligo
•
•
Overlapping technical and scientific expertise requirements, with
quality lab space and production processes in place
✓ Customer contacts
✓ Expert team
✓ GMP documentation
Oligo Lab space
Team purely focused on oligonucleotide business, including senior
and process scientists
•
Oligo Pilot GMP plant, Q4
•
Oligo first customer end H2
• Modified Oligo GMP plant, Q4
Pipeline building
•
Build early-stage pipeline
Scale-up team and
infrastructure
Establish track record
Plan and design large-
scale capacity
Required scale-up and GMP manufacturing know-how, available at
PolyPeptide
GLOBAL SUPPORT FOR A QUALITY SOLUTION
16
2020
2021
2022
2023
2024
2025+
PolyPeptide
GROUPView entire presentation